Association between 6-thioguanine nucleotides levels and clinical remission in inflammatory disease: A meta-analysis

Inflammatory Bowel Diseases

Volumn 20, Issue 3, 2014, Pages 464-471

  Moreau, Amelie Carla ^a   Paul, Stephane ^a   Del Tedesco, Emilie ^a   Rinaudo Gaujous, Melanie ^a   Boukhadra, Nabila ^a   Genin, Christian ^a   Peyrin Biroulet, Laurent ^b   Roblin, Xavier ^a  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

6 TGN; IBD; Therapeutic drug monitoring; Thiopurines

Indexed keywords

NUCLEOTIDE DERIVATIVE; TIOGUANINE;

ARTICLE; DISEASE ASSOCIATION; ERYTHROCYTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFLAMMATORY BOWEL DISEASE; META ANALYSIS (TOPIC); PRIORITY JOURNAL; REMISSION;

DRUG MONITORING; GUANINE NUCLEOTIDES; HUMANS; INFLAMMATORY BOWEL DISEASES; PROGNOSIS; REMISSION INDUCTION; THIONUCLEOTIDES;

EID: 84898726547     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000439068.71126.00     Document Type: Article

References (40)

1. Chevaux J-B, Peyrin-Biroulet L, Sparrow MP. Optimizing thiopurine therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2011;17: 1428-1435.
2. Gisbert JP, Linares PM, Mcnicholl AG, et al. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther. 2009;30:126-137.
3. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002;50: 485-489.
4. Khan KJ, Dubinsky MC, Ford AC, et al. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and metaanalysis. Am J Gastroenterol. 2011;106:630-642.
5. Cuffari C, Théorêt Y, Latour S, et al. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut. 1996;39: 401-406.
6. Osterman MT, Kundu R, Lichtenstein GR, et al. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology. 2006;130:1047-1053.
7. Kwan LY, Devlin SM, Mirocha JM, et al. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease. Dig Liver Dis. 2008;40:425-432.
8. González-Lama Y, Bermejo F, López-Sanromán A, et al. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients. Aliment Pharmacol Ther. 2011;34:544-554.
9. Cangemi G, Barabino A, Barco S, et al. A validated HPLC method for the monitoring of thiopurine metabolites in whole blood in paediatric patients with inflammatory bowel disease. Int J Immunopathol Pharmacol. 2012; 25:435-444.
10. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940-987.
11. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6:991-1030.
12. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis. 2010;4:28-62.
13. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol. 2009;104:465-483; quiz 464, 484.
14. Cucherat M. Méta-analyse des essais thérapeutiques. France: Masson; 1997.
15. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283:2008-2012.
16. Cuffari C, Hunt S, Bayless TM. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment Pharmacol Ther. 2000;14: 1009-1014.
17. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705-713.
18. Belaiche J, Desager JP, Horsmans Y, et al. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol. 2001;36:71-76.
19. Gupta P, Gokhale R, Kirschner BS. 6-Mercaptopurine metabolite levels in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001;33:450-454.
20. Lowry P, Franklin C, Weaver A, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut. 2001;49:665-670.
21. Su C, Wang S, Deren J, et al. GR. Measurement of 6-TG levels in patients with IBD: are all groups identical? Gastroenterology. 2002;122:A77. [A645].
22. Bourreille A, Doubremelle M, Ganiere C, et al. Should 6-thioguanine nucleotides be monitored in patients with inflammatory bowel disease treated by azathioprine? Gastroenterology. 2003;124:A194.
23. Achkar J-P, Stevens T, Easley K, et al. Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:339-345.
24. Goldenberg BA, Rawsthorne P, Bernstein CN. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am J Gastroenterol. 2004;99:1744-1748.
25. Wusk B, Kullak-Ublick GA, Rammert C, et al. Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis. Eur J Gastroenterol Hepatol 2004;16:1407-1413.
26. Ooi CY, Bohane TD, Lee D, et al. Thiopurine metabolite monitoring in paediatric inflammatory bowel disease. Aliment Pharmacol Ther. 2007; 25:941-947.
27. Waljee AK, Joyce JC, Wang S, et al. Algorithms outperform metabolite tests in predicting response of patients with inflammatory bowel disease to thiopurines. Clin Gastroenterol Hepatol. 2010;8:143-150.
28. Gilissen LPL, Wong DR, Engels LG, et al. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy. J Crohns Colitis. 2012;6:698-707.
29. Parodi A, Arrigo S, Cangemi G, et al. Correlation between 6-thioguanine levels and clinical responde in children with inflammatory bowel diseasetreated with thiopurines: a preliminary single centre study. Dig Liver Dis. 2011;43S:S397-S447, CO33.
30. Dervieux T, Meyer G, Barham R, et al. Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy. Clin Chem. 2005;51:2074-2084.
31. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
32. Erdmann GR, France LA, Bostrom BC, et al. A reversed phase high performance liquid chromatography approach in determining total red blood cell concentrations of 6-thioguanine, 6-mercaptopurine, methylthioguanine, and methylmercaptopurine in a patient receiving thiopurine therapy. Biomed Chromatogr. 1990;4:47-51.
33. Shipkova M, Armstrong VW, Wieland E, et al. Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods. Clin Chem. 2003;49:260-268.
34. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ. 1997;315:1533-1537.
35. Lennard L, Singleton HJ. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr. 1992;583:83-90.
36. Wright S, Sanders DS, Lobo AJ, et al. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut. 2004;53:1123-1128.
37. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut. 2001;48:642-646.
38. Reinshagen M, Schütz E, Armstrong VW, et al. 6-Thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active Crohn disease: results from a randomized, controlled, open trial. Clin Chem. 2007;53:1306-1314.
39. de Graaf P, de Boer NKH, Jharap B, et al. Stability of thiopurine metabolites: a potential analytical bias. Clin Chem. 2008;54:216-218.
40. Roblin X, Serre-Debeauvais F, Phelip J-M, et al. 6-Tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine. Aliment Pharmacol Ther. 2005;21:829-839.